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The bone marrow is the origin of all hematopoietic lineages and an important homing 
site for memory cells of the adaptive immune system. It has recently emerged as a 
graft-versus-host disease (GvHD) target organ after allogeneic stem cell transplantation 
(alloHSCT), marked by depletion of both hematopoietic progenitors and niche-forming 
cells. Serious effects on the restoration of hematopoietic function and immunological 
memory are common, especially in patients after myeloablative conditioning therapy. 
Cytopenia and durable immunodeficiency caused by the depletion of hematopoietic 
progenitors and destruction of bone marrow niches negatively influence the outcome of 
alloHSCT. The complex balance between immunosuppressive and cell-depleting treat-
ments, GvHD and immune reconstitution, as well as the desirable graft-versus-tumor 
(GvT) effect remains a great challenge for clinicians.
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For many decades, allogeneic stem cell transplantation (alloHSCT) has been used for the treatment 
of hematological malignancies. Alloreactive T cells contained within the donor bone marrow prepa-
rations have eventually been recognized as both causative for the life-threatening graft-versus-host 
disease (GvHD) and the beneficial graft-versus-tumor (GvT) effect (1, 2). Great scientific effort has 
since been put into further delineating the impact of T cell subpopulations and associated effector 
functions on GvHD development in order to segregate GvHD from GvT but no clinically feasible 
solution to this apparent dilemma has yet emerged.
Skin, liver, and intestine are regarded as the principal target organs of GvHD that can be affected 
to varying degrees or not at all. Individual outcomes of alloHSCT are hardly predictable because the 
complex interplay of multiple factors is just starting to be understood. GvHD is commonly correlated 
with long-term cytopenic conditions, resulting in mortality due to infections and bleeding complica-
tions (3). Besides toxicity resulting from conditioning treatment, alloreactivity in the bone marrow 
has been deemed responsible for the observed defects in hematopoiesis. Recent studies conclusively 
demonstrated niche-forming cells in the bone marrow as targets of GvHD (4, 5).
Here, we address the molecular and cellular causes of GvHD in general and focus next on the 
sequence of events leading to hematopoietic failure and immunodeficiency as a consequence of 
alloreactivity in the bone.
SOURCe OF ALLOReACTiviTY
In both GvHD and GvT, donor T cells react against host cells expressing alloantigens. In major 
histocompatibility complex (MHC)-mismatched alloHSCT, a large fraction of donor T cells targets 
monomorphic host proteins presented as peptides in the context of recipient MHC molecules. 
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In donors, developing T cells are negatively selected exclusively 
against proteins presented as peptides bound to self-MHC 
molecules. Therefore, a large fraction of these T cells express 
T cell receptors with high affinity for host MHC molecules or the 
presented peptides in their context (6). Due to the comparably 
large number of reactive T cell clones (7), the ensuing GvHD 
response in MHC-mismatched settings is usually very severe 
and can be difficult to control despite the application of intensive 
immunosuppressive treatments.
In MHC-matched transplant settings, donor T cells target 
minor histocompatibility antigens (MiHAs), polymorphic genes 
presented via MHC molecules as processed peptides. Negative 
selection against these antigens is absent in the donor thymus due 
to lack of expression. Therefore, T cell receptors with high affinity 
to recipient MiHAs exist in small frequencies within the donor 
T cell repertoire. Respective T cell clones can become activated 
in an inflammatory environment as caused by pretransplant regi-
mens and may trigger GvHD or react against MiHA-expressing 
tumor tissue. Whereas in MHC-mismatched alloHSCT, alloan-
tigens are exclusively presented by host antigen-presenting cells 
(APCs), in an MHC-matched setting they can additionally be 
of donor origin due to cross presentation after uptake of host 
cell fragments (8, 9). Although only a fraction of polymorphic 
genes can be presented as peptide in a given MHC combination 
and single MiHA differences are not regarded as sufficient for 
the induction of GvHD in clinical settings, novel tools such as 
global genome association studies and in  silico prediction have 
been widely used to identify an ever-growing set of clinically 
relevant MiHAs among thousands of polymorphic genes (10, 11), 
explaining the high incidence of GvHD even in MHC-matched 
transplantations.
Alloreactive donor T cells exert their effector function via both 
soluble and cell-contact-dependent cytotoxic factors. Upon acti-
vation by APCs, mainly CD4 T cells produce Th1-type cytokines, 
including interferon-γ (IFN-γ), tumor-necrosis factor-α (TNF-α), 
and interleukin-1 (IL-1). These soluble factors are systemically 
transported through the blood to GvHD target organs and locally 
act by rendering various cell types more susceptible to the ensu-
ing alloreactive T cell response.
Antigen-specific target cell killing is principally mediated 
by the perforin–granzyme pathway and Fas–Fas ligand (FasL) 
interaction, both of which are employed by both CD4 and CD8 
cytotoxic T lymphocytes (CTLs). Upon binding to their cognate 
antigen, CTLs can secrete perforin and granzyme, which in 
combination leads to lysis and rapid apoptosis of target cells. In 
an inflammatory context, Fas can be upregulated on target cells 
making them susceptible for cytotoxic killing by FasL-expressing 
T cells (12).
Due to broad functional overlap, complex differential 
expression of Fas in various organs under different pretreat-
ment conditioning and incompatible GvHD models used in 
respective studies, the individual impact of FasL and perforin–
granzyme pathways from CD4 and CD8 effectors is still under 
discussion (13). However, the FasL–Fas pathway appears to 
be more associated with the establishment of donor chimer-
ism and GvHD severity and more important for CD4 effector 
function, whereas GvT is suggested to be more attributable 
to perforin–granzyme cytotoxicity without any salient T cell 
subset preference (14–16).
Ultimately, even a complete lack of both cytolytic pathways 
does not abolish GvHD, clearly demonstrating the existence of 
additional cytotoxic effectors in the T cell arsenal (17). TNF-
related apoptosis-inducing ligand (TRAIL) and TNF-like weak 
inducer of apoptosis (TWEAK) are both expressed by T cells 
and have been assumed to partially compensate under these 
conditions by signaling through their cognate receptors death 
receptor 4 (DR4) or DR5 and TWEAK receptor (CD266), 
respectively (18).
GvHD AnD iMMUne ReCOnSTiTUTiOn
In order to facilitate bone marrow engraftment and to diminish 
tumor burden, patients are treated with conditioning prior to 
alloHSCT, leading to tissue damage and immunosuppression. 
Whereas acute GvHD (aGvHD) occurs in the early phase after 
alloHSCT or immediately after termination of immunosuppres-
sive regimen, chronic GvHD (cGvHD) emerges later, is clinically 
less defined and shares many characteristics with autoimmune 
diseases, including de novo generation of autoreactive T cell 
clones and the development of autoantibody titers (19, 20).
In affected patients, harsh treatment with immunosuppres-
sive drugs can control the effects of GvHD, though at the cost of 
delayed immune reconstitution and mitigation of desired GvT 
effects. Even without immunosuppression, outcomes of sub-
lethal GvHD include generalized cytopenia and a dramatically 
delayed immune reconstitution of all lymphoid lineages (21). 
Consequently, lethal GvHD and opportunistic infections are 
responsible for high mortality in relapse-free patients within the 
first year after alloHSCT (22, 23).
The discovery of strong alloreactivity against thymic tissues 
has suggested a link between aGvHD and impaired T cell recon-
stitution after alloHSCT (24). Allogeneic T cells targeting host 
T cells and also the thymic architecture can easily be understood 
as causative for T cell deficiencies with additional implications for 
B cell immunity, since both B cell effector function and memory 
formation largely depend on interaction with CD4 T cells (25). 
Thymic GvHD also adds a new layer of understanding on the 
frequently observed autoimmune traits of ensuing cGvHD. The 
thymus is the principal organ of T lymphocyte development, in 
charge of generating an extremely diverse set of T cell clones, 
while eliminating autoreactive clones (26). Arguably, the strin-
gent and finely tuned T cell selection process in the thymus can 
be unhinged by destruction of self-APCs, which could allow 
potentially autoreactive clones to escape into the periphery and 
to cause autoimmune symptoms.
Using more refined mouse models of both MHC-matched 
and mismatched HSCT, the bone marrow has been established 
as an additional target of GvHD. In these studies, GvHD gener-
ally affected hematopoiesis and lymphoid development (27). 
However, serial bone marrow transfer experiments strongly 
suggest that GvHD progression depends on the targeting of 
non-hematopoietic cells of the bone marrow (5). Infiltrating 
T cells of donor origin were clearly associated with both impaired 
hematopoiesis and destruction of specialized niche-forming 
FiGURe 1 | Bone marrow niches and their response to preconditioning and alloHSCT. Left: niches for hematopoietic stem cells (HSCs) are located at the 
endosteal border and comprise osteoblasts and specialized mesenchymal cells partly immunoprotected by adjacent regulatory T cells (Treg). Alternatively, HSCs can 
seed into perivascular niches (not shown). B cell progenitors and recirculating memory T, B (memCD4, memCD8, and memBC), and plasma cells occupy additional 
specialized perivascular niches. Upon preconditioning, bone marrow cells are differently affected by the treatment as indicated by the flash size. Right: after 
alloHSCT, alloreactive T cells are massively activated (not shown) leads to systemic influx of soluble inflammatory factors into the bone marrow where they cause 
upregulation of Fas on various cell types and harm donor and recipient HSCs alike. Infiltrating alloreactive donor T cells deplete residual host hematopoietic cells and 
support disintegration of endostial and perivascular niches by means of cytolytic and soluble factors. Consequently, efflux of hematopoietic lineages and seeding 
capacity for donor-derived hematopoietic stem and memory cells is diminished.
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cells, including osteoblasts and sinusoidal vascular endothelial 
cells (28). In several studies, GvHD effects seemed to selectively 
impair B cell development (14, 29). For the first time, Mensen 
et  al. could translate these findings to the human setting by 
correlating impaired immune reconstitution after HSCT with 
both GvHD and T cell infiltration into the bone marrow and 
by demonstrating a striking reduction in osteoblasts in these 
patients (4). This closely resembles the findings in mouse models 
of GvHD allowing a generalized view on immunodeficiency after 
alloHSCT.
iMPLiCATiOnS OF BOne MARROw 
niCHe DeSTRUCTiOn
In adult individuals, the bone marrow is both the origin of hemat-
opoiesis and the ultimate harbor of immune cells comprising the 
immunological memory, namely, long-lived plasma cells and 
memory CD4 and CD8 T cells (30–34). Furthermore, hemato-
logical malignancies either originate or later become manifest in 
the bone marrow. All immunological functions strictly depend 
on a complex organization of niche-forming stromal cells of 
mesenchymal and endothelial origin providing important devel-
opmental cues to hematopoietic progenitors or crucial survival 
signals to memory cells.
Figure 1 proposes a model of bone marrow GvHD by bring-
ing together data from clinical studies and various scientific 
investigations using mouse models or in  vitro culture systems. 
Figure 1 (left) depicts bone marrow homeostasis with a focus on 
niche constituents and points out cells susceptible to standard 
preconditioning treatment. Figure 1 (right) shows cell types and 
effector mechanisms involved in acute bone marrow GvHD and 
clarifies how multiple niches are impacted by alloreactivity as 
explained in the following section.
A mutual starting point for all hematopoietic lineages is the 
endosteum, where self-renewing hematopoietic stem cells (HSCs) 
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reside in niches made up of specialized osteoblasts and nestin-
expressing MSCs (35, 36) presumed to be osteogenic progenitors. 
Alternatively, HSCs can also be maintained in perivascular niches 
made up of CXCL12-expressing MSCs adjacent to vascular 
endothelial cells of bone marrow sinusoids (37, 38). Although 
both the endosteal and the perivascular niche seem to equally 
support HSC maintenance, the interplay between both niches 
has not been established yet (39). During proliferation of niche-
derived cells, individual lineage decisions are made in a step-wise 
fashion during migration from the endosteum toward the mar-
row sinusoids, where cells ultimately exit the bone marrow and 
enter the blood circulation. For B cells, the maturation from HSC 
to transitional B cell exiting the bone marrow requires multiple 
dedicated stromal cells providing stage-specific signals (40).
Stromal and hematopoietic cells are differently affected by the 
conditioning treatment prior to alloHSCT. HSCs, hematopoietic 
progenitor cells, B cells, myeloid cells, and, to a lesser extent, 
T cells are depleted by irradiation and/or anti-mitotic drugs (27).
In contrast, mesenchymal and endothelial cells as well as 
memory T and B cells are resting cells and were shown to be 
comparably resistant to depletion (41, 42). Danger signals medi-
ated by tissue damage trigger APC maturation and increased 
presentation of alloantigens via MHCI and II.
Upon alloHSCT, donor T cells, contained within the bone 
marrow preparations, circulate into secondary lymphoid organs 
and become activated mainly via interaction with dendritic cells 
(DC), APCs that express alloantigens along with high levels of the 
costimulatory molecules CD80 and CD86 upon preconditioning 
(9). At least for CD8 T cells, the initiation of aGvHD is strictly 
dependent on host APC activity (43). Activated T cells start pro-
liferating and secrete large amounts of inflammatory cytokines 
and thereby initiate the acute phase of GvHD.
In the bone marrow, systemic inflammation leads to drastic 
changes in bone marrow-resident cells. TNF-α and IL-1 signaling 
stimulates upregulation of MHCII, CD40, and adhesion signals in 
endothelial cells, and blood vessel walls become more permeable, 
facilitating activation and entrance of innate immune cells and 
alloreactive lymphocytes into the bone marrow (44). Furthermore, 
prolonged systemic levels of IFN-γ in combination with TNF-α 
initiate endothelial cell death, which can be expected to impair 
maintenance of perivascular niches for memory and stem cells (45).
Osteoblasts constitutively express MHCI and potentially 
respond to inflammatory signals by upregulation of MHCII, 
Fas, and CD40, making them easy targets for alloreactive T cell 
response (46, 47). Mesenchymal cells also respond to IFN-γ by 
upregulation of MHCI and MHCII but demonstrate a striking 
inability to activate alloreactive T cells (48, 49). Even more, mes-
enchymal cells are capable of actively inhibiting T cell effector 
function by direct and indirect mechanisms, including interfer-
ence with DC maturation and secretion of IL-10 (50). However, 
it is unclear whether MSCs themselves have the potential to resist 
strong alloreactivity. In a likely scenario, perivascular MSCs 
constituting important survival niches for memory and HSCs 
would at least display reduced niche capacities when adjacent 
endothelial cells became apoptotic.
Concomitantly, donor HSCs and progenitor cells enter the 
bone marrow via sinusoids and migrate to cell-specific niches 
that have been made available by depletion of host hematopoietic 
cells. However, HSC survival and proliferative capacity is also 
affected by soluble inflammatory factors, resulting in reduced 
HSC seeding under aGvHD conditions (51, 52).
Subsequently, activated alloreactive donor T cells infiltrate the 
bone marrow and exert their cytolytic effector functions by attack-
ing cells presenting host alloantigens. The outcome of the ensuing 
immune response is impacted by multiple factors, including the 
immunogenic strength, level of presentation and number of 
individual alloantigens on host cells, the degree of inflammation 
caused by conditioning treatment, the size of the residual host 
T cell population capable of mounting a host-versus-graft 
response, and the naive repertoire of donor T cells.
Ultimately, the remaining hematopoietic host cells, including 
HSCs and memory cells, are depleted mainly via CD8-derived 
Fas–FasL and complete donor chimerism is established 
(14, 27). At that stage, the patient’s immunological memory 
should be deleted with grave implications for immunity against 
recurring pathogens. As recipient APCs of hematopoietic origin 
are depleted, alloantigen is largely presented by donor-derived 
APCs. However, due to the poor engraftment potential of donor-
derived mesenchymal cells, the majority of niche-forming cells 
in the bone marrow remain host mesenchymal and endothelial 
cells continuously expressing alloantigens (53). Osteoblasts and 
endothelial cells present MHCI and II at least under inflamma-
tory conditions and therefore, most niche-forming cells of the 
bone marrow, albeit poor antigen presenters, constitute targets 
of alloreactivity under harsh conditions such as precondition-
ing and aGvHD (47). Additionally, continuous presentation of 
phagocytosed alloantigens by donor-derived APCs via MHCII, 
and to a lesser extent via cross presentation to MHCI, can support 
indirect niche destruction mainly via alloreactive CD4 T cells 
secreting soluble factors.
In sum, bone marrow GvHD leads to gradual reduction of 
aforementioned niches, which diminishes hematopoiesis and 
seeding of donor-derived memory cells into their respective 
bone marrow niches (Figure  1, right). Although the endosteal 
niche has recently been reported to be immune-privileged by 
means of regulatory T cells (54), steep reduction in osteoblast 
numbers argues against any protective environment at least 
under GvHD conditions. The bone marrow niche size for distinct 
cell populations is strictly limited by the number of respective 
niche-forming cells; and hence, any reduction in their numbers 
directly decreases the specific niche-capacity of the bone marrow. 
IL-7-expressing perivascular stroma cells in the bone marrow 
comprise the niche for memory T cells and loss of these cells due 
to alloreactivity negatively impacts donor memory T cell seeding 
and prolongs the preexisting immunosuppressive state of patients 
receiving alloHSCT (31, 55). Furthermore, it is not surprising 
that the B cell developmental program, requiring several distinct 
populations of niche-forming cells for individual maturation 
steps, proves to be the most affected cell population (29, 40). 
Hypothetically, the tightly regulated process of central tolerance 
that removes potentially autoreactive B cell clones could readily 
be unhinged by GvHD-mediated niche damage, possibly lead-
ing to secondary autoimmune symptoms synonymous with the 
chronic form of GvHD. Interestingly, cGvHD has been shown to 
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be associated with autoantibody titers (56). All factors described 
above work in combination at manifesting a stage of prolonged 
immunosuppression.
FUTURe DiReCTiOnS
The rationale of using alloHSCT for the treatment of hema-
tological disorders is the rapid replacement of the patient’s 
defective hematopoietic system, whereas harnessing the 
alloreactivity of donor T cells for rejection of persistent tumor. 
However, these very T cells are also responsible for GvHD and 
accelerated immunodeficiency, a price we are willing to pay 
for a chance of relapse-free survival. However, the hidden cost 
is obviously much higher, considering that donor T cells are 
also responsible for bone marrow GvHD, which potentially 
leads to extensive destruction of niche-forming cells by not 
yet fully understood mechanisms. This greatly influences the 
kinetics of comprehensive immune reconstitution, because the 
replenishment of destroyed niches is apparently very slow. 
Besides broad effects on hematopoiesis, the seeding capacity 
of recirculating memory T cells into the bone marrow might 
be impacted by bone marrow GvHD, as we could show for B 
cell development. In consequence, a large fraction of treated 
patients remains vulnerable to otherwise harmless infections 
for months or years after treatment. Further research is needed 
to better protect dedicated bone marrow niches from GvHD. 
Alternatively, novel transplantation protocols should dem-
onstrate improved seeding capacity of donor mesenchymal 
stem cells to rapidly replenish destroyed host niche-forming 
cells and to harness their unique immunosuppressive 
properties (57).
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